“According to a new report published by Introspective Market Research, Neurological Biomarkers Market by Type, Application, and End User , The Global Neurological Biomarkers Market Size Was Valued at USD 9.40 Billion in 2023 and is Projected to Reach USD 28.97 Billion by 2032, Growing at a CAGR of 13% from 2024 to 2032. ”
The neurological biomarkers market plays a critical role in advancing the diagnosis, monitoring, and treatment of neurological disorders by enabling precise detection of disease progression and therapeutic response. Neurological biomarkers include proteins, genetic markers, imaging indicators, and metabolites that provide measurable insights into conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, and other neurodegenerative and neuropsychiatric disorders.
Compared to conventional diagnostic approaches, neurological biomarkers offer higher accuracy, earlier disease detection, and improved patient stratification. These advantages are driving adoption across clinical research, drug development, and routine diagnostics. The growing burden of neurological disorders, combined with rising healthcare expenditure and technological advancements in molecular diagnostics and neuroimaging, is significantly fueling market growth globally.
Market Segmentation
The Neurological Biomarkers Market is segmented into Type, Application, and End User.
By Type, the market is categorized into Protein Biomarkers, Genetic Biomarkers, Imaging Biomarkers, and Metabolic Biomarkers.
By Application, the market is categorized into Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Epilepsy, and Other Neurological Disorders.
By End User, the market is categorized into Hospitals, Diagnostic Laboratories, Academic & Research Institutes, and Pharmaceutical & Biotechnology Companies.
Growth Driver
The primary growth driver of the neurological biomarkers market is the rising prevalence of neurodegenerative diseases worldwide. Aging populations, increased life expectancy, and lifestyle-related risk factors have led to a surge in conditions such as Alzheimer’s and Parkinson’s disease. This growing patient pool has intensified demand for early and accurate diagnostic tools. Neurological biomarkers enable early-stage detection and disease monitoring, supporting personalized treatment strategies. Additionally, increased investments in neuroscience research and biomarker-based drug development by pharmaceutical companies are accelerating market expansion.
Market Opportunity
A significant market opportunity lies in the integration of neurological biomarkers with precision medicine and companion diagnostics. Advances in genomics, proteomics, and artificial intelligence are enabling the discovery of novel biomarkers with improved sensitivity and specificity. Emerging economies present untapped potential due to improving healthcare infrastructure and rising awareness of neurological disorders. Furthermore, expanding clinical trials for disease-modifying therapies and biomarker-driven drug approvals are expected to create substantial growth opportunities for market participants over the forecast period.
Detailed Segmentation
Neurological Biomarkers Market, Segmentation
The Neurological Biomarkers Market is segmented on the basis of Type, Application, and End User.
Type
The Type segment is further classified into Protein Biomarkers, Genetic Biomarkers, and Imaging Biomarkers. Among these, the Protein Biomarkers sub-segment accounted for the highest market share in 2023. Protein biomarkers such as beta-amyloid, tau proteins, and neurofilament light chain are widely used due to their proven clinical relevance and accessibility through blood and cerebrospinal fluid testing. Their extensive application in Alzheimer’s and Parkinson’s disease diagnostics continues to support segment dominance.
Application
The Application segment is further classified into Alzheimer’s Disease, Parkinson’s Disease, and Multiple Sclerosis. Among these, the Alzheimer’s Disease sub-segment accounted for the highest market share in 2023. The rising prevalence of Alzheimer’s disease, coupled with increased research funding and regulatory support for biomarker-based diagnostics, has driven strong demand. Biomarkers are increasingly used for early detection, disease staging, and monitoring therapeutic outcomes in Alzheimer’s patients.
Some of The Leading/Active Market Players Are
- Roche Diagnostics (Switzerland)
• Thermo Fisher Scientific Inc. (USA)
• Abbott Laboratories (USA)
• Bio-Rad Laboratories Inc. (USA)
• QIAGEN N.V. (Netherlands)
• Siemens Healthineers (Germany)
• Merck KGaA (Germany)
• Danaher Corporation (USA)
• Agilent Technologies Inc. (USA)
• Becton, Dickinson and Company (USA)
• Quanterix Corporation (USA)
• Myriad Genetics Inc. (USA)
• PerkinElmer Inc. (USA)
• Enzo Biochem Inc. (USA)
and other active players.
Key Industry Developments
In March 2024 , a leading diagnostics company launched a novel blood-based biomarker test for early Alzheimer's detection.
The new assay demonstrated high sensitivity in identifying early pathological changes, reducing reliance on invasive cerebrospinal fluid testing and supporting wider clinical adoption.
In September 2023 , a major pharmaceutical company expanded its biomarker-driven neuroscience research collaboration.
The partnership focuses on identifying novel biomarkers to accelerate drug discovery and improve success rates in clinical trials for neurodegenerative diseases.
Key Findings of the Study
- Protein biomarkers dominated the market due to high clinical utility
• Alzheimer's disease remained the leading application segment
• North America led the market owing to advanced healthcare infrastructure
• Rising neurological disease burden is a key growth driver
• Biomarker-based precision medicine is an emerging trend
More Info :- https://introspectivemarketresearch.com/reports/neurological-biomarkers-market/
About Us
At Introspective Market Research Private Limited , we are a forward-thinking research consulting firm committed to driving growth in the Neurological Biomarkers Market . With deep insights, strategic solutions, and holistic research, we empower businesses to achieve success and dominance in the global Neurological Biomarkers industry.
📞 Contact Us
Introspective Market Research Pvt. Ltd.
Phone: +91-91753-37569
Email: sales@introspectivemarketresearch.com
Web: www.introspectivemarketresearch.com